New triple-drug attack shows promise for hard-to-treat ovarian cancer
NCT ID NCT07286240
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs for people whose ovarian cancer has returned after standard treatment. The drugs include a dual-target immunotherapy (QL1706), chemotherapy, and an oral anti-angiogenic agent (anlotinib). The goal is to see if this combo can shrink tumors or slow cancer growth. About 40 adults with recurrent ovarian cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lipai Chen
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••